{"id":"risperidone-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"15-25%","effect":"Weight gain"},{"rate":"40-50%","effect":"Hyperprolactinemia"},{"rate":"10-15%","effect":"Sedation"},{"rate":"5-10%","effect":"Orthostatic hypotension"},{"rate":"15-20%","effect":"Metabolic syndrome"},{"rate":"1-5%","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. At higher doses, it provides more potent dopamine antagonism, making it suitable for treatment-resistant psychotic disorders.","oneSentence":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:15.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Treatment-resistant psychosis (at higher doses)"}]},"trialDetails":[{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT01499563","phase":"PHASE2","title":"Study of a Novel Antipsychotic ITI-007 in Schizophrenia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":335},{"nctId":"NCT00539071","phase":"PHASE4","title":"High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":160},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT03955549","phase":"PHASE3","title":"Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial","status":"COMPLETED","sponsor":"Agiad Psychiatry Hospital","startDate":"2019-05-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":99},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00571688","phase":"PHASE4","title":"Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2007-11","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02687984","phase":"PHASE1","title":"PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-02","conditions":"Schizophrenia","enrollment":44},{"nctId":"NCT02964923","phase":"","title":"Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-04","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT02768649","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2011-04","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT00576732","phase":"PHASE4","title":"A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Autistic Disorder, Autism","enrollment":96},{"nctId":"NCT01855074","phase":"PHASE4","title":"An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2007-11","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":80},{"nctId":"NCT00722176","phase":"PHASE2","title":"Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-06","conditions":"Schizophrenia","enrollment":220},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00140166","phase":"PHASE4","title":"Treatment of Acute Schizophrenia With Vitamin Therapy","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2005-07","conditions":"Acute Schizophrenia","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":124,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperidone high dose","genericName":"Risperidone high dose","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}